PMC:3724972 / 3111-3768 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"For most patients with CD, primary treatment is transsphenoidal surgery to remove the pituitary adenoma. However, success rates are variable (reported as 65 to 90 %) and dependent on the surgeon’s expertise [11]. Published 5- and 10-year recurrence rates are as high as 25 and 56 %, respectively [12, 13], and many patients develop deficiencies of other pituitary hormones post-surgery [11]. Patients who fail to achieve or maintain remission require secondary treatment, including radiotherapy and/or adrenalectomy—both of which are associated with subsequent hormone deficiencies [11]. Thus, additional treatment options for patients with CD are required.","tracks":[{"project":"2_test","denotations":[{"id":"23673515-18413427-63233580","span":{"begin":208,"end":210},"obj":"18413427"},{"id":"23673515-16268808-63233581","span":{"begin":297,"end":299},"obj":"16268808"},{"id":"23673515-18056770-63233582","span":{"begin":301,"end":303},"obj":"18056770"},{"id":"23673515-18413427-63233583","span":{"begin":387,"end":389},"obj":"18413427"},{"id":"23673515-18413427-63233584","span":{"begin":583,"end":585},"obj":"18413427"}],"attributes":[{"subj":"23673515-18413427-63233580","pred":"source","obj":"2_test"},{"subj":"23673515-16268808-63233581","pred":"source","obj":"2_test"},{"subj":"23673515-18056770-63233582","pred":"source","obj":"2_test"},{"subj":"23673515-18413427-63233583","pred":"source","obj":"2_test"},{"subj":"23673515-18413427-63233584","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ec93a9","default":true}]}]}}